RAD and RADX Related Headlines
Go Back- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
- Radiopharm Theranostics Reports Business Update
- Radiopharm presents early trial data for HER2-targeted cancer therapy
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm moves to next dose level in cancer drug trial
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- Radiopharm Theranostics partners with Siemens for RAD101 supply
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm doses first patient in RAD 402 prostate cancer trial
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics reports 90% success rate in brain imaging trial
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics doses first patient in cancer drug trial
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics gets approval for prostate cancer drug trial
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics advances to third cohort in cancer drug trial
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
- Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
- Radiopharm gets approval to raise dose in cancer drug trial
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
- Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
- Radiopharm Theranostics adds cancer specialist to scientific advisory board
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
- Radiopharm Theranostics (RADX) and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
RAD and RADX Related Press Releases
Go Back- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
- Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
- Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
- Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
RAD and RADX Related SEC Filings
Go Back- Form 6-K Radiopharm Theranostics For: Jun 03
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Voliotis Dimitris
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: HOPPER PAUL
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Laurita Aaron James
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Donnelly Noel
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Turner Ian Lawrence
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Larkin Hester Denise
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Canevari Riccardo
- Form 3 Radiopharm Theranostics For: Mar 18 Filed by: Goodwin Bruce Michael
